Needle-free Drug Delivery Device Market To Reach $21.6 Billion By 2030

Needle-free Drug Delivery Device Market Growth & Trends

The global needle-free drug delivery device market size is expected to reach USD 21.6 billion by 2030, registering to grow at a CAGR of 7.5% from 2024 to 2030 according to a new report by Grand View Research, Inc. Rising usage of injections in healthcare settings such as hospitals, clinics, and ambulatory surgical centers has led to spread of infectious diseases such as Hepatitis B, Hepatitis C, and AIDS, especially in developing countries. This acts as a key driver for the needle-less drug delivery devices industry. Furthermore, rising collaborations between market players is further likely to increase competitiveness of this market. For instance, PharmaJet and Mundipharma entered into a partnership in 2018 for distributing its needle free injectors over 120 markets globally.

Moreover, technological advancements in healthcare are expected to open new avenues for market players in applications such as cancer, AIDS, and Ataxic Cerebral Palsy. For instance, polycarbonate materials are being utilized in needle free injectors owing to their advantages such as design flexibility, toughness, light weight, and process ability. The most recent example of such technology is needle-free injection insulin delivery device manufactured by QS Medical Technology Co. (QS) in September 2018.

 Request a free sample copy or view report summary: Needle-free Drug Delivery Devices Market Report

Needle-free Drug Delivery Device Market Report Highlights

• In 2023, jet injectors segment held the largest share of 29.2%, owing to the key advantages such as fast working mechanism and insulin distribution over a larger area in lower layer of an individual's skin.

• In 2023, insulin delivery held the largest revenue share of 33.6%. Increasing number of people suffering from diabetes due to unhealthy lifestyle are driving the segmental growth. According to the Centers for Disease Control and Prevention, about 38.4 million individuals were affected by diabetes globally in 2023, of which 11.6% were U.S. citizens.

• North America dominated the regional segment by capturing the largest share of 43.4% in 2023. Increased awareness of people about healthcare and tendency to adopt advanced devices are the prime drivers of the market.

Needle-free Drug Delivery Devices Market Segmentation

Grand View Research has segmented the global needle-free drug delivery device market based on technology, application and region:

Needle-free Drug Delivery Devices Technology Outlook (Revenue, USD Million, 2017 - 2030)

• Jet Injectors

• Inhaler technology

• Transdermal patch technology

• Novel needle-free technologies

Needle-free Drug Delivery Devices Application Outlook (Revenue, USD Million, 2017 - 2030)

• Vaccine delivery

• Pain management

• Insulin delivery for diabetes

• Pediatric injections

• Others

Needle-free Drug Delivery Devices Regional Outlook (Revenue, USD Million, 2017 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Needle-free Drug Delivery Device Market

• PenJet

• Zealand Pharma

• UCB S.A.

• PharmaJet

• 3M

• Verdict Media Limited

• INJEX Pharma AG

• Antares Pharma

• Endo Pharmaceuticals Inc.

• Bioject Medical Technologies, Inc.

• Crossject SA